KRAS and neoplasm: These findings are consistent with the results of Rounds 1 and 2 of the physician survey, conducted in 2012–2013 before the latest label changes for panitumumab, where the majority (99.0%) of participants correctly identified that KRAS testing should be performed in patients with mCRC and confirmed wild-type KRAS tumours, in accordance with the then-correct indication for panitumumab [18].